Drugs by condition
Drugs approved for breast cancer
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
78
Still marketed, NDA or BLA
Drug classes
12
Novel drugs
39
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for breast cancer.
All approved drugs for breast cancer, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 144 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
RANK Ligand Inhibitor (10)
- Prolia Denosumab · Amgen · 2010
- Boncresa Denosumab-Mobz · Amneal Pharms LLC · 2025
- Denosumab-Dssb Denosumab-Dssb · Samsung Bioepis CO LTD · 2025
- Osvyrti Denosumab-Desu · Accord Biopharma Inc. · 2025
- Enoby Denosumab-Qbde · Hikma Pharmaceuticals USA INC · 2025
- Aukelso Denosumab-Kyqq · Biocon Biologics INC · 2025
- Bilprevda Denosumab-Nxxp · Shanghai Henlius Biotech · 2025
- Conexxence Denosumab-Bnht · Fresenius Kabi USA LLC · 2025
- Osenvelt Denosumab-Bmwo · Celltrion INC · 2025
- Jubbonti Denosumab-Bbdz · Sandoz INC · 2024
HER2/neu Receptor Antagonist (9)
- Margenza Margetuximab-Cmkb · Tersera Therapeutics LLC · 2020
- Perjeta Pertuzumab · Genentech · 2012
- Herceptin Trastuzumab · Genentech · 1998
- Kanjinti Trastuzumab-Anns · Amgen INC · 2019
- Trazimera Trastuzumab-Qyyp · Pfizer INC · 2019
- Herceptin Hylecta Trastuzumab and Hyaluronidase-Oysk · Genentech INC · 2019
- Ontruzant Trastuzumab-Dttb · Samsung Bioepis CO LTD · 2019
- Herzuma Trastuzumab-Pkrb · Celltrion INC · 2018
- Ogivri Trastuzumab-Dkst · Mylan Gmbh · 2017
Kinase Inhibitor (8)
- Revtorpyk Gedatolisib · Celcuity · 2026
- Itovebi Inavolisib · Genentech INC · 2024
- Tukysa Tucatinib · Seagen · 2020
- Verzenio Abemaciclib · Eli Lilly and CO · 2017
- Ibrance Palbociclib · Pfizer · 2015
- Afinitor Everolimus · Novartis · 2009
- Ibrance Palbociclib · Pfizer · 2019
- Afinitor Disperz Everolimus · Novartis Pharm · 2012
Microtubule Inhibitor (6)
- Beizray Docetaxel · Zhuhai · 2024
- Paclitaxel Paclitaxel · Teva Pharms INC · 2023
- Paclitaxel Paclitaxel · Am Regent · 2022
- Docetaxel Docetaxel · Accord Hlthcare · 2011
- Docetaxel Docetaxel · Hospira INC · 2011
- Abraxane Paclitaxel · Bristol-Myers · 2005
Estrogen Receptor Antagonist (4)
- Inluriyo Imlunestrant Tosylate · Eli Lilly and CO · 2025
- Faslodex Fulvestrant · Astrazeneca · 2002
- Cligavyx Fulvestrant · Avyxa Holdings · 2019
- Fulvestrant Fulvestrant · Fresenius Kabi USA · 2019
Aromatase Inhibitor (3)
Endoglycosidase (2)
- Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
- Phesgo Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf · Genentech INC · 2020
Radioactive Diagnostic Agent (1)
- Cerianna Fluoroestradiol F-18 · Ge Healthcare · 2020
Programmed Death Receptor-1 Blocking Antibody (1)
- Keytruda Pembrolizumab · Merck Sharp Dohme · 2014
Estrogen (1)
- Premarin Estrogens, Conjugated · Wyeth Pharms · 1942
Poly(ADP-Ribose) Polymerase Inhibitor (1)
- Lynparza Olaparib · Astrazeneca · 2017
Class not listed in FDA's data (32)
- Etcamah Camizestrant · Astrazeneca · 2026
- Veppanu Vepdegestrant · Rigel Pharms · 2026
- Datroway Datopotamab Deruxtecan-Dlnk · Daiichi Sankyo INC · 2025
- Lumisight Pegulicianine Acetate · Lumicell · 2024
- Truqap Capivasertib · Astrazeneca · 2023
- Trodelvy Sacituzumab Govitecan-Hziy · Immunomedics INC · 2020
- Enhertu Fam-Trastuzumab Deruxtecan-Nxki · Daiichi Sankyo · 2019
- Piqray Alpelisib · Novartis · 2019
- Nerlynx Neratinib Maleate · Puma Biotech · 2017
- Kisqali Ribociclib Succinate · Novartis · 2017
- Lymphoseek Kit Technetium Tc-99m Tilmanocept · Cardinal Health 414 · 2013
- Kadcyla Ado-Trastuzumab Emtansine · Genentech · 2013
- Halaven Eribulin Mesylate · Eisai INC · 2010
- Ixempra Kit Ixabepilone · R-Pharm US LLC · 2007
- Tykerb Lapatinib Ditosylate · Novartis · 2007
- Ellence Epirubicin Hydrochloride · Pfizer INC · 1999
- Evista Raloxifene Hydrochloride · Lilly · 1997
- Taxotere Docetaxel · Sanofi Aventis US · 1996
- Miraluma Technetium Tc-99m Sestamibi Kit · Shine · 1990
- Zoladex Goserelin Acetate · Tersera · 1989
- Oxderys Doxorubicin Hydrochloride · Avyxa Holdings · 2026
- Avgemsi Gemcitabine Hydrochloride · Avyxa Holdings · 2025
- Hercessi Trastuzumab-Strf · Accord Biopharma Inc. · 2024
- Talzenna Talazoparib Tosylate · Pfizer · 2024
- Docetaxel Docetaxel · Avyxa Holdings · 2022
- Docetaxel Docetaxel · Actavis · 2013
- Gemcitabine Hydrochloride Gemcitabine Hydrochloride · Hospira INC · 2011
- Docetaxel Docetaxel · Sandoz · 2011
- Soltamox Tamoxifen Citrate · Mayne Pharma Commrcl · 2005
- Doxorubicin Hydrochloride Doxorubicin Hydrochloride · Pfizer · 1987
- An-Sulfur Colloid Technetium Tc-99m Sulfur Colloid Kit · Sun Pharm Inds INC · 1978
- Methotrexate Preservative Free Methotrexate Sodium · Hospira · 1959
Drugs in development for breast cancer
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
- JSKN003Phase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer
- KN026PlacboPhase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer
- LHRH AgonistPhase 36 trials
Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
4 discontinued brand-name drugs whose label still names it
More on breast cancer: recruiting trials · published research
Related in oncology: Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.